1-9 of 9
Nozar Azarnia, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4249.
https://doi.org/10.1182/blood-2019-132127
Published: 2019
Journal Articles

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Guillermo Garcia-Manero, MD, Shyamala C. Navada, MD, Pierre Fenaux, MD PhD, Patrick S. Zbyszewski, MBA, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Steven M. Fruchtman, MD, Lewis R. Silverman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4268.
https://doi.org/10.1182/blood-2019-132149
Published: 2019
Journal Articles

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Guillermo Garcia-Manero, MD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Bernard Brownstein, MD, Hannes Loferer, PhD, Nozar Azarnia, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Lewis R. Silverman, MD
Journal: Blood
Blood (2016) 128 (22): 4324.
https://doi.org/10.1182/blood.V128.22.4324.4324
Published: 2016
Journal Articles

Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Ghulam J Mufti, FRCP, FRCPath, MD, Lewis R. Silverman, MD, Steven Best, PhD, Steve Fructman, MD, Nozar Azarnia, PhD, Michael E. Petrone, MD MPH, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2015) 126 (23): 5257.
https://doi.org/10.1182/blood.V126.23.5257.5257
Published: 2015
Journal Articles

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Shyamala C. Navada, MD, Lewis R. Silverman, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Pierre Fenaux, MD PhD, Steve Fruchtman, MD, Nozar Azarnia, PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2015) 126 (23): 910.
https://doi.org/10.1182/blood.V126.23.910.910
Published: 2015
Journal Articles

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Francois Wilhelm, MD PhD, Katherine Hearn, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Nozar Azarnia, PhD, Lewis R. Silverman, MD
Journal: Blood
Blood (2014) 124 (21): 3252.
https://doi.org/10.1182/blood.V124.21.3252.3252
Published: 2014
Journal Articles

Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy

Ghulam J Mufti, FRCP, FRCPath, MD, Steven Best, PhD, Nicholas Lea, PhD, Lewis R. Silverman, MD, Guillermo Garcia-Manero, MD, Nozar Azarnia, PhD, Francois Wilhelm, MD PhD, Gudrun Goehring, MD
Journal: Blood
Blood (2014) 124 (21): 3258.
https://doi.org/10.1182/blood.V124.21.3258.3258
Published: 2014
Journal Articles

Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)

Lewis R. Silverman, MD, Pierre Fenaux, MD PhD, Aref Al-Kali, MD, Maria R. Baer, MD, Mikkael A. Sekeres, MD MS, Gail J. Roboz, MD, Gianluca Gaidano, MD PhD, Bart L. Scott, MD, Peter L. Greenberg, MD PhD, Uwe Platzbecker, MD, David P. Steensma, MD, Suman Kambhampati, MD, Karl-Anton Kreuzer, MD, Lucy A Godley, MD PhD, Robert Collins, Ehab Atallah, MD, Shyamala C. Navada, MD, Francois Wilhelm, MD PhD, Nozar Azarnia, PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2014) 124 (21): 3259.
https://doi.org/10.1182/blood.V124.21.3259.3259
Published: 2014
Journal Articles

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Guillermo Garcia-Manero, MD, Pierre Fenaux, MD PhD, Aref Al-Kali, MD, Maria R. Baer, MD, Mikkael A. Sekeres, MD MS, Gail J. Roboz, MD, Gianluca Gaidano, MD PhD, Bart L. Scott, MD, Peter L. Greenberg, MD PhD, Uwe Platzbecker, MD, David P. Steensma, MD, Suman Kambhampati, MD, Karl-Anton Kreuzer, MD, Lucy A Godley, MD PhD, Robert Collins, Ehab Atallah, MD, Francois Wilhelm, MD PhD, Isabelle E. Wilhelm, MD, Nozar Azarnia, PhD, Manoj Maniar, PhD, Lewis R. Silverman, MD
Journal: Blood
Blood (2014) 124 (21): 163.
https://doi.org/10.1182/blood.V124.21.163.163
Published: 2014